Introduktion
Den här sidan ger en omfattande analys av den kända insiderhandelshistoriken för Neil Kumar. Insiders är tjänstemän, styrelseledamöter eller betydande investerare i ett företag. Det är olagligt för insiders att göra affärer i sina företag baserat på specifik, icke-offentlig information. Detta betyder inte att det är olagligt för dem att göra några affärer i sina egna företag. De måste dock rapportera alla affärer till SEC via ett formulär 4. Trots dessa restriktioner tyder akademisk forskning på att insiders – i allmänhet – tenderar att överträffa marknaden i sina egna företag.
Genomsnittlig handelslönsamhet
Den genomsnittliga handelslönsamheten är den genomsnittliga avkastningen av alla köp på den öppna marknaden som insidern gjort under de senaste tre åren. För att beräkna detta undersöker vi alla oplanerade köp på öppen marknad som görs av insidern, exklusive alla affärer som markerats som en del av en 10b5-1-handelsplan. Vi beräknar sedan den genomsnittliga prestandan för dessa affärer under 3, 6 och 12 månader, med ett genomsnitt av var och en av dessa varaktigheter för att generera ett slutgiltigt resultatmått för varje affär. Slutligen tar vi ett genomsnitt av alla prestationsmått för att beräkna ett prestationsmått för insidern. Denna lista inkluderar endast insiders som har gjort minst tre affärer under de senaste två åren.
Om lönsamheten för denna insiderhandel är "N/A", så har insidern antingen inte gjort några köp på den öppna marknaden under de senaste tre åren, eller så är affärerna de har gjort för nya för att kunna beräkna ett tillförlitligt resultatmått.
Uppdateringsfrekvens: Dagligen
Företag med rapporterade insiderpositioner
SEC-anmälningarna visar att Neil Kumar har rapporterat innehav eller affärer i följande företag:
| Värdepapper | Titel | Senaste rapporterade innehav |
|---|---|---|
| US:BBIO / BridgeBio Pharma, Inc. | Chief Executive Officer, Director | 243 327 |
| US:LIAN / LianBio - Depositary Receipt (Common Stock) | Director | 5 002 792 |
| Chief Executive Officer, Director, 10% Owner | 24 575 501 |
Hur man tolkar diagrammen
Följande diagram visar aktieutvecklingen för värdepapper efter varje icke-planerad handel på öppen marknad som görs av Neil Kumar. Icke-planerad handel är affärer som inte gjordes som en del av en 10b5-1-handelsplan. Aktieutvecklingen visas som kumulativ procentuell förändring av aktiekursen. Till exempel, om en insiderhandel gjordes den 1 januari 2019, kommer diagrammet att visa den dagliga procentuella förändringen av värdepapperet fram till idag. Om aktiekursen skulle gå från $10 till $15 under denna tid, skulle den kumulativa procentuella förändringen i aktiekursen vara 50%. En förändring i priset från 10 USD till 20 USD skulle vara 100 % och en prisändring på 10 USD till 5 USD skulle vara -50 %.
I slutändan försöker vi avgöra hur nära insiders affärer korrelerar med överavkastning (positiv eller negativ) i aktiekursen för att se om insidern tar tid för sina affärer att dra nytta av insiderinformation. Tänk på situationen där en insider gjorde detta. I den här situationen förväntar vi oss antingen (a) positiv avkastning efter köp eller (b) negativ avkastning efter försäljning. I fallet med (a) skulle KÖP-diagrammet visa en serie uppåtlutande kurvor, vilket indikerar positiv avkastning efter varje köptransaktion. I fallet med (b) skulle SALE-diagrammet visa en serie nedåtlutande kurvor, vilket indikerar negativ avkastning efter varje försäljningstransaktion.
Detta är dock inte tillräckligt för att dra slutsatser. Om till exempel aktiekursen i bolaget var i en icke-cyklisk stigning under många år, skulle vi förvänta oss att alla tomter efter köpet skulle vara uppåtlutande. Likaså skulle icke-cykliska nedgångar under många år resultera i nedåtlutande post-trade tomter. Inget av dessa diagram skulle tyda på insiderhandel.
Den starkaste indikatorn skulle vara en situation där aktiekursen var extremt cyklisk, och det fanns både positiva signaler i KÖP-diagrammet och negativa plotter på SALE-diagrammet. Denna situation skulle i hög grad tyda på en insider som tog tid för affärer till sin ekonomiska fördel.
Insiderköp BBIO / BridgeBio Pharma, Inc. - Analys av kortsiktig vinst
I det här avsnittet analyserar vi lönsamheten för varje oplanerat insiderköp på en öppen marknad som görs i BBIO / BridgeBio Pharma, Inc.. Denna analys hjälper till att förstå om insidern konsekvent genererar onormal avkastning och är värd att följa. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Tabellen nedan visar de senaste öppna marknadsköpen som inte var en del av en automatisk handelsplan.
| Handelsdatum | Ticker | Insider | Rapporterade aktier |
Rapporterad pris |
Justerade aktier |
Justerat pris |
Kostnadsgrund | Dagar till max |
Pris vid max |
Max vinst ($) |
Maximal avkastning (%) |
|---|---|---|---|---|---|---|---|
| Det finns inga kända oplanerade öppna marknadstransaktioner för denna insider |
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderförsäljning - Analys av kortsiktig förlust
I det här avsnittet analyserar vi det kortsiktiga undvikandet av förluster för varje oplanerad insiderförsäljning på öppen marknad som görs i BBIO / BridgeBio Pharma, Inc.. Ett konsekvent mönster för att undvika förluster kan tyda på att framtida försäljningstransaktioner kan förutsäga prisnedgångar. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Följande tabell visar de senaste försäljningarna på den öppna marknaden som inte ingick i en automatisk handelsplan.
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderhandelshistorik
Den här tabellen visar den fullständiga listan över insideraffärer gjorda av Neil Kumar som avslöjats för Securities Exchange Commission (SEC).
| Fildatum | Transaktionsdatum | Schema | Ticker | Värdepapper | Kode | Aktier | Återstående aktier | Procentuell förandring | Aktie pris |
Transaktionsvärde | Återstående värde |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-26 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −800 | 243 327 | −0,33 | 70,92 | −56 735 | 17 256 483 |
| 2026-05-26 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −11 250 | 244 127 | −4,41 | 70,48 | −792 916 | 17 206 413 |
| 2026-05-26 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −5 072 | 255 377 | −1,95 | 69,22 | −351 102 | 17 678 090 |
| 2026-05-26 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −6 725 | 260 449 | −2,52 | 68,30 | −459 334 | 17 789 318 |
| 2026-05-26 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −2 256 | 267 174 | −0,84 | 67,57 | −152 435 | 18 052 600 |
| 2026-05-19 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
F - Taxes | −36 236 | 269 430 | −11,85 | 66,13 | −2 396 287 | 17 817 406 | |
| 2026-05-19 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 6 519 | 305 666 | 2,18 | ||||
| 2026-05-19 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 11 553 | 299 147 | 4,02 | ||||
| 2026-05-19 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 19 599 | 287 594 | 7,31 | ||||
| 2026-05-19 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 33 544 | 267 995 | 14,31 | ||||
| 2026-05-11 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −950 | 4 358 447 | −0,02 | 68,35 | −64 930 | 297 889 828 |
| 2026-05-11 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −5 076 | 4 359 397 | −0,12 | 67,35 | −341 846 | 293 585 771 |
| 2026-05-11 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −13 974 | 4 364 473 | −0,32 | 66,65 | −931 374 | 290 894 308 |
| 2026-05-11 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −950 | 555 686 | −0,17 | 68,35 | −64 930 | 37 979 860 |
| 2026-05-11 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −5 077 | 556 636 | −0,90 | 67,35 | −341 913 | 37 486 930 |
| 2026-05-11 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −13 973 | 561 713 | −2,43 | 66,65 | −931 307 | 37 438 452 |
| 2026-05-11 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −449 | 4 378 447 | −0,01 | 69,09 | −31 022 | 302 511 720 |
| 2026-05-11 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −8 334 | 4 378 896 | −0,19 | 68,38 | −569 858 | 299 417 961 |
| 2026-05-11 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −11 217 | 4 387 230 | −0,26 | 67,49 | −757 090 | 296 115 650 |
| 2026-05-11 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −450 | 575 686 | −0,08 | 69,09 | −31 091 | 39 774 779 |
| 2026-05-11 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −8 333 | 576 136 | −1,43 | 68,38 | −569 790 | 39 394 739 |
| 2026-05-11 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −11 217 | 584 469 | −1,88 | 67,50 | −757 091 | 39 448 735 |
| 2026-04-13 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −20 000 | 4 398 447 | −0,45 | 74,60 | −1 492 076 | 328 140 860 |
| 2026-04-13 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −20 000 | 595 686 | −3,25 | 74,60 | −1 492 096 | 44 441 035 |
| 2026-04-13 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −7 800 | 4 418 447 | −0,18 | 75,53 | −589 124 | 333 719 558 |
| 2026-04-13 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −5 128 | 4 426 247 | −0,12 | 74,57 | −382 379 | 330 051 517 |
| 2026-04-13 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −7 072 | 4 431 375 | −0,16 | 73,64 | −520 801 | 326 338 420 |
| 2026-04-13 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −7 500 | 615 686 | −1,20 | 75,55 | −566 661 | 46 518 033 |
| 2026-04-13 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −5 300 | 623 186 | −0,84 | 74,60 | −395 403 | 46 492 418 |
| 2026-04-13 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −7 200 | 628 486 | −1,13 | 73,64 | −530 240 | 46 284 474 |
| 2026-03-16 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −9 759 | 4 438 447 | −0,22 | 69,23 | −675 568 | 307 251 937 |
| 2026-03-16 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −10 241 | 4 448 206 | −0,23 | 68,39 | −700 345 | 304 196 795 |
| 2026-03-16 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −10 310 | 635 686 | −1,60 | 69,20 | −713 449 | 43 989 280 |
| 2026-03-16 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −9 690 | 645 996 | −1,48 | 68,36 | −662 441 | 44 162 483 |
| 2026-03-16 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −300 | 4 458 447 | −0,01 | 70,15 | −21 045 | 312 760 057 |
| 2026-03-16 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −5 815 | 4 458 747 | −0,13 | 69,29 | −402 929 | 308 952 376 |
| 2026-03-16 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −13 885 | 4 464 562 | −0,31 | 68,47 | −950 687 | 305 682 310 |
| 2026-03-16 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −300 | 655 686 | −0,05 | 70,15 | −21 045 | 45 996 373 |
| 2026-03-16 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −5 363 | 655 986 | −0,81 | 69,32 | −371 750 | 45 471 375 |
| 2026-03-16 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −14 337 | 661 349 | −2,12 | 68,48 | −981 809 | 45 289 709 |
| 2026-02-23 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −602 | 234 451 | −0,26 | 72,80 | −43 826 | 17 068 267 |
| 2026-02-23 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −8 528 | 235 053 | −3,50 | 72,08 | −614 702 | 16 942 714 |
| 2026-02-23 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −18 923 | 243 581 | −7,21 | 71,03 | −1 344 190 | 17 302 703 |
| 2026-02-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
F - Taxes | −30 970 | 262 504 | −10,55 | 75,25 | −2 330 492 | 19 753 426 | |
| 2026-02-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 11 554 | 293 474 | 4,10 | ||||
| 2026-02-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 19 600 | 281 920 | 7,47 | ||||
| 2026-02-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 33 544 | 262 320 | 14,66 | ||||
| 2026-02-12 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −3 961 | 4 478 447 | −0,09 | 73,25 | −290 145 | 328 048 482 |
| 2026-02-12 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −4 404 | 4 482 408 | −0,10 | 72,65 | −319 938 | 325 634 390 |
| 2026-02-12 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −3 775 | 4 486 812 | −0,08 | 71,46 | −269 754 | 320 619 061 |
| 2026-02-12 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −7 860 | 4 490 587 | −0,17 | 70,70 | −555 706 | 317 486 746 |
| 2026-02-12 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −3 994 | 675 686 | −0,59 | 73,25 | −292 574 | 49 496 364 |
| 2026-02-12 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −4 484 | 679 680 | −0,66 | 72,64 | −325 695 | 49 368 557 |
| 2026-02-12 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −3 716 | 684 164 | −0,54 | 71,44 | −265 477 | 48 877 771 |
| 2026-02-12 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −7 806 | 687 880 | −1,12 | 70,69 | −551 796 | 48 625 343 |
| 2026-02-12 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −5 960 | 4 498 447 | −0,13 | 72,27 | −430 751 | 325 119 409 |
| 2026-02-12 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −14 040 | 4 504 407 | −0,31 | 71,80 | −1 008 006 | 323 395 252 |
| 2026-02-12 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −5 799 | 695 686 | −0,83 | 72,28 | −419 165 | 50 285 784 |
| 2026-02-12 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −14 201 | 701 485 | −1,98 | 71,80 | −1 019 657 | 50 367 886 |
| 2026-01-12 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −1 855 | 4 518 447 | −0,04 | 78,10 | −144 882 | 352 906 525 |
| 2026-01-12 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −10 677 | 4 520 302 | −0,24 | 77,46 | −827 016 | 350 132 196 |
| 2026-01-12 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −6 067 | 4 530 979 | −0,13 | 76,53 | −464 289 | 346 742 230 |
| 2026-01-12 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −1 401 | 4 537 046 | −0,03 | 75,61 | −105 928 | 343 040 604 |
| 2026-01-12 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −375 | 715 686 | −0,05 | 78,19 | −29 322 | 55 960 920 |
| 2026-01-12 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −10 519 | 716 061 | −1,45 | 77,61 | −816 365 | 55 572 492 |
| 2026-01-12 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −6 955 | 726 580 | −0,95 | 76,72 | −533 569 | 55 741 256 |
| 2026-01-12 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −2 151 | 733 535 | −0,29 | 75,75 | −162 943 | 55 566 743 |
| 2026-01-12 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −300 | 4 538 447 | −0,01 | 75,20 | −22 561 | 341 306 191 |
| 2026-01-12 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −8 135 | 4 538 747 | −0,18 | 74,38 | −605 061 | 337 580 655 |
| 2026-01-12 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −11 565 | 4 546 882 | −0,25 | 73,65 | −851 811 | 334 896 956 |
| 2026-01-12 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −400 | 735 686 | −0,05 | 75,16 | −30 064 | 55 294 307 |
| 2026-01-12 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −8 085 | 736 086 | −1,09 | 74,38 | −601 340 | 54 748 089 |
| 2026-01-12 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −11 515 | 744 171 | −1,52 | 73,64 | −848 018 | 54 804 176 |
| 2025-12-16 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −1 700 | 228 776 | −0,74 | 75,24 | −127 910 | 17 213 381 |
| 2025-12-16 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −28 311 | 230 476 | −10,94 | 74,60 | −2 111 992 | 17 193 440 |
| 2025-12-16 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
F - Taxes | −30 964 | 258 787 | −10,69 | 75,15 | −2 326 945 | 19 447 843 | |
| 2025-12-16 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 60 975 | 289 751 | 26,65 | ||||
| 2025-12-08 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −7 712 | 4 558 447 | −0,17 | 73,75 | −568 758 | 336 184 555 |
| 2025-12-08 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −12 288 | 4 566 159 | −0,27 | 73,04 | −897 529 | 333 517 276 |
| 2025-12-08 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −7 483 | 755 686 | −0,98 | 73,76 | −551 951 | 55 739 928 |
| 2025-12-08 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −12 517 | 763 169 | −1,61 | 73,05 | −914 324 | 55 746 901 |
| 2025-12-08 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −5 700 | 4 578 447 | −0,12 | 74,80 | −426 358 | 342 466 004 |
| 2025-12-08 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −12 200 | 4 584 147 | −0,27 | 74,42 | −907 970 | 341 169 639 |
| 2025-12-08 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −2 100 | 4 596 347 | −0,05 | 73,16 | −153 626 | 336 247 603 |
| 2025-12-08 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −5 708 | 775 686 | −0,73 | 74,80 | −426 939 | 58 018 675 |
| 2025-12-08 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −12 192 | 781 394 | −1,54 | 74,42 | −907 381 | 58 154 701 |
| 2025-12-08 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −2 100 | 793 586 | −0,26 | 73,16 | −153 638 | 58 059 625 |
| 2025-11-24 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −5 456 | 228 776 | −2,33 | 66,71 | −363 986 | 15 262 310 |
| 2025-11-24 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −14 299 | 234 232 | −5,75 | 65,90 | −942 361 | 15 436 826 |
| 2025-11-24 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −6 401 | 248 531 | −2,51 | 64,97 | −415 877 | 16 147 208 |
| 2025-11-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
F - Taxes | −32 855 | 254 932 | −11,42 | 66,39 | −2 181 243 | 16 924 935 | |
| 2025-11-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 11 554 | 287 787 | 4,18 | ||||
| 2025-11-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 19 599 | 276 233 | 7,64 | ||||
| 2025-11-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 33 544 | 256 634 | 15,04 | ||||
| 2025-11-10 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −220 | 795 686 | −0,03 | 62,79 | −13 815 | 49 963 988 |
| 2025-11-10 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −7 546 | 795 906 | −0,94 | 61,87 | −466 839 | 49 239 282 |
| 2025-11-10 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −12 234 | 803 452 | −1,50 | 61,13 | −747 862 | 49 114 860 |
| 2025-11-10 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −200 | 4 598 447 | 0,00 | 62,80 | −12 561 | 288 805 464 |
| 2025-11-10 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −7 308 | 4 598 647 | −0,16 | 61,87 | −452 156 | 284 524 728 |
| 2025-11-10 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −12 492 | 4 605 955 | −0,27 | 61,14 | −763 762 | 281 608 549 |
| 2025-11-10 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −100 | 815 686 | −0,01 | 64,39 | −6 439 | 52 522 022 |
| 2025-11-10 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −7 371 | 815 786 | −0,90 | 63,56 | −468 472 | 51 848 177 |
| 2025-11-10 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −12 529 | 823 157 | −1,50 | 62,91 | −788 184 | 51 783 819 |
| 2025-11-10 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −100 | 4 618 447 | 0,00 | 64,39 | −6 439 | 297 381 802 |
| 2025-11-10 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −7 324 | 4 618 547 | −0,16 | 63,55 | −465 416 | 293 493 421 |
| 2025-11-10 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −12 576 | 4 625 871 | −0,27 | 62,91 | −791 166 | 291 017 245 |
| 2025-10-10 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −20 000 | 835 686 | −2,34 | 54,80 | −1 096 046 | 45 797 515 |
| 2025-10-10 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −20 000 | 835 686 | −2,34 | 54,80 | −1 096 046 | 45 797 515 |
| 2025-10-10 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −11 295 | 855 686 | −1,30 | 55,09 | −622 226 | 47 138 544 |
| 2025-10-10 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −8 705 | 866 981 | −0,99 | 54,39 | −473 450 | 47 153 623 |
| 2025-10-10 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −11 294 | 4 658 447 | −0,24 | 55,09 | −622 171 | 256 627 323 |
| 2025-10-10 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −8 706 | 4 669 741 | −0,19 | 54,39 | −473 504 | 253 978 807 |
| 2025-09-08 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −800 | 875 686 | −0,09 | 53,80 | −43 040 | 47 111 381 |
| 2025-09-08 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −16 900 | 876 486 | −1,89 | 53,16 | −898 450 | 46 596 362 |
| 2025-09-08 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −2 300 | 893 386 | −0,26 | 51,96 | −119 514 | 46 422 570 |
| 2025-09-08 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −900 | 4 678 447 | −0,02 | 53,80 | −48 424 | 251 721 034 |
| 2025-09-08 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −16 800 | 4 679 347 | −0,36 | 53,16 | −893 125 | 248 764 381 |
| 2025-09-08 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −2 300 | 4 696 147 | −0,05 | 51,95 | −119 496 | 243 986 439 |
| 2025-09-08 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −5 442 | 895 686 | −0,60 | 51,85 | −282 187 | 46 444 454 |
| 2025-09-08 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −14 558 | 901 128 | −1,59 | 51,16 | −744 739 | 46 098 735 |
| 2025-09-08 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −5 475 | 4 698 447 | −0,12 | 51,85 | −283 902 | 243 634 680 |
| 2025-09-08 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −14 525 | 4 703 922 | −0,31 | 51,15 | −742 960 | 240 607 492 |
| 2025-08-22 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −428 | 223 090 | −0,19 | 49,25 | −21 079 | 10 987 272 |
| 2025-08-22 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −25 728 | 223 518 | −10,32 | 48,81 | −1 255 848 | 10 910 472 |
| 2025-08-19 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
F - Taxes | −32 855 | 249 246 | −11,65 | 51,32 | −1 686 119 | 12 791 305 | |
| 2025-08-19 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 64 697 | 282 101 | 29,76 | ||||
| 2025-08-11 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −8 205 | 915 686 | −0,89 | 46,71 | −383 252 | 42 771 327 |
| 2025-08-11 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −8 205 | 915 686 | −0,89 | 46,71 | −383 252 | 42 771 327 |
| 2025-08-11 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −11 795 | 923 891 | −1,26 | 45,88 | −541 162 | 42 388 673 |
| 2025-08-11 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −11 795 | 923 891 | −1,26 | 45,88 | −541 162 | 42 388 673 |
| 2025-08-11 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −13 216 | 935 686 | −1,39 | 45,64 | −603 152 | 42 702 838 |
| 2025-08-11 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −13 216 | 935 686 | −1,39 | 45,64 | −603 152 | 42 702 838 |
| 2025-08-11 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −6 784 | 948 902 | −0,71 | 45,09 | −305 909 | 42 788 553 |
| 2025-08-11 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −6 784 | 948 902 | −0,71 | 45,09 | −305 909 | 42 788 553 |
| 2025-07-03 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −20 000 | 955 686 | −2,05 | 42,73 | −854 514 | 40 832 353 |
| 2025-07-03 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −20 000 | 4 758 447 | −0,42 | 42,73 | −854 536 | 203 313 213 |
| 2025-07-03 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −1 600 | 975 686 | −0,16 | 42,89 | −68 628 | 41 849 612 |
| 2025-07-03 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −18 400 | 977 286 | −1,85 | 42,50 | −782 092 | 41 539 541 |
| 2025-07-03 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −1 700 | 4 778 447 | −0,04 | 42,88 | −72 903 | 204 919 399 |
| 2025-07-03 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −18 300 | 4 780 147 | −0,38 | 42,50 | −777 777 | 203 163 418 |
| 2025-05-20 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −75 000 | 4 798 447 | −1,54 | 33,40 | −2 504 978 | 160 266 690 |
| 2025-05-20 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −400 | 217 404 | −0,18 | 33,75 | −13 499 | 7 336 841 |
| 2025-05-20 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −25 756 | 217 804 | −10,57 | 33,32 | −858 265 | 7 257 861 |
| 2025-05-20 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
F - Taxes | −32 854 | 243 560 | −11,89 | 33,84 | −1 111 779 | 8 242 070 | |
| 2025-05-20 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 64 696 | 276 414 | 30,56 | ||||
| 2025-04-24 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −75 000 | 4 873 447 | −1,52 | 34,11 | −2 558 025 | 166 218 657 |
| 2025-03-27 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −75 000 | 4 948 447 | −1,49 | 36,87 | −2 764 942 | 182 428 952 |
| 2025-02-27 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −37 101 | 5 023 447 | −0,73 | 33,79 | −1 253 524 | 169 726 199 |
| 2025-02-27 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −37 899 | 5 060 548 | −0,74 | 33,36 | −1 264 447 | 168 838 099 |
| 2025-02-19 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −76 | 211 718 | −0,04 | 36,56 | −2 779 | 7 740 410 |
| 2025-02-19 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −31 467 | 211 794 | −12,94 | 36,14 | −1 137 246 | 7 654 426 |
| 2025-02-19 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
F - Taxes | −23 996 | 243 261 | −8,98 | 34,90 | −837 460 | 8 489 809 | |
| 2025-02-19 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 55 539 | 267 257 | 26,23 | ||||
| 2025-01-30 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −4 000 | 5 098 447 | −0,08 | 36,82 | −147 284 | 187 729 917 |
| 2025-01-30 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −269 068 | 5 102 447 | −5,01 | 36,34 | −9 777 985 | 185 423 944 |
| 2025-01-30 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −326 932 | 5 371 515 | −5,74 | 36,29 | −11 863 381 | 194 916 165 |
| 2024-12-27 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
G - Gift | 4 685 725 | 5 698 447 | 462,69 | ||||
| 2024-12-27 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
G - Gift | −4 685 725 | 211 718 | −95,68 | ||||
| 2024-11-20 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −1 875 | 4 897 443 | −0,04 | 22,76 | −42 680 | 111 478 046 |
| 2024-11-20 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −25 514 | 4 899 318 | −0,52 | 22,39 | −571 146 | 109 674 173 |
| 2024-11-19 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
F - Taxes | −28 148 | 4 924 832 | −0,57 | 23,72 | −667 671 | 116 817 015 | |
| 2024-11-19 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 55 537 | 4 952 980 | 1,13 | ||||
| 2024-08-20 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −11 197 | 4 897 443 | −0,23 | 25,13 | −281 367 | 123 066 866 |
| 2024-08-20 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −16 192 | 4 897 443 | −0,33 | 24,39 | −394 889 | 119 438 350 |
| 2024-08-20 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
F - Taxes | −28 148 | 4 924 832 | −0,57 | 24,40 | −686 811 | 120 165 901 | |
| 2024-08-20 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 55 537 | 4 952 980 | 1,13 | ||||
| 2024-05-17 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
F - Taxes | −30 748 | 4 897 443 | −0,62 | 31,04 | −954 418 | 152 016 631 | |
| 2024-05-17 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 60 667 | 4 928 191 | 1,25 | ||||
| 2024-02-21 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
F - Taxes | −47 922 | 4 867 524 | −0,97 | 37,21 | −1 783 178 | 181 120 568 | |
| 2024-02-21 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 102 249 | 4 915 446 | 2,12 | ||||
| 2023-11-20 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −200 | 4 813 197 | 0,00 | 29,55 | −5 910 | 142 229 971 |
| 2023-11-20 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −51 352 | 4 813 397 | −1,06 | 29,10 | −1 494 128 | 140 049 636 |
| 2023-11-20 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
F - Taxes | −50 697 | 4 864 749 | −1,03 | 28,86 | −1 463 115 | 140 396 656 | |
| 2023-11-20 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 102 249 | 4 915 446 | 2,12 | ||||
| 2023-08-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −51 552 | 4 813 197 | −1,06 | 28,59 | −1 473 784 | 137 601 120 |
| 2023-08-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
F - Taxes | −50 698 | 4 864 749 | −1,03 | 29,80 | −1 510 800 | 144 969 520 | |
| 2023-08-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 102 250 | 4 915 447 | 2,12 | ||||
| 2023-05-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −51 552 | 4 813 197 | −1,06 | 14,01 | −722 218 | 67 430 483 |
| 2023-05-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
F - Taxes | −50 697 | 4 864 749 | −1,03 | 14,09 | −714 321 | 68 544 313 | |
| 2023-05-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 102 249 | 4 915 446 | 2,12 | ||||
| 2023-05-05 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −120 000 | 1 012 722 | −10,59 | 14,18 | −1 701 744 | 14 361 613 |
| 2023-04-07 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −120 000 | 1 132 722 | −9,58 | 15,46 | −1 855 656 | 17 516 186 |
| 2023-03-03 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −120 000 | 1 252 722 | −8,74 | 10,96 | −1 315 224 | 13 730 084 |
| 2023-02-21 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −44 798 | 4 813 197 | −0,92 | 12,70 | −569 073 | 61 142 523 |
| 2023-02-21 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
F - Taxes | −23 908 | 4 857 995 | −0,49 | 12,64 | −302 197 | 61 405 057 | |
| 2023-02-21 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 68 706 | 4 881 903 | 1,43 | ||||
| 2023-02-06 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −120 000 | 1 372 722 | −8,04 | 11,01 | −1 320 696 | 15 107 904 |
| 2023-01-06 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −120 000 | 1 492 722 | −7,44 | 7,67 | −920 856 | 11 454 850 |
| 2022-12-21 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | −200 000 | 995 686 | −16,73 | ||||
| 2022-11-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | −34 640 | 4 813 197 | −0,71 | 9,40 | −325 606 | 45 242 608 | |
| 2022-11-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
F - Taxes | −34 066 | 4 847 837 | −0,70 | 9,64 | −328 396 | 46 733 149 | |
| 2022-11-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 68 706 | 4 881 903 | 1,43 | ||||
| 2022-08-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
F - Taxes | −27 697 | 4 813 197 | −0,57 | 11,08 | −306 883 | 53 330 223 | |
| 2022-08-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 68 705 | 4 840 894 | 1,44 | ||||
| 2022-05-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Restricted Stock Units |
M - Exercise | −61 182 | 428 274 | −12,50 | ||||
| 2022-05-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Restricted Stock Units |
M - Exercise | −2 394 | 26 336 | −8,33 | ||||
| 2022-05-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Restricted Stock Units |
M - Exercise | −5 129 | 41 035 | −11,11 | ||||
| 2022-05-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
F - Taxes | −23 759 | 4 772 189 | −0,50 | 6,74 | −160 136 | 32 164 554 | |
| 2022-05-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 68 705 | 4 795 948 | 1,45 | ||||
| 2022-03-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Restricted Stock Units |
A - Award | 489 456 | 489 456 | |||||
| 2022-02-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Restricted Stock Units |
M - Exercise | −2 394 | 28 730 | −7,69 | ||||
| 2022-02-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Restricted Stock Units |
M - Exercise | −5 130 | 46 164 | −10,00 | ||||
| 2022-02-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
F - Taxes | −3 085 | 4 727 243 | −0,07 | 8,84 | −27 271 | 41 788 828 | |
| 2022-02-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 7 524 | 4 730 328 | 0,16 | ||||
| 2021-12-07 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Stock Option (right to buy) |
A - Award | 786 072 | 786 072 | |||||
| 2021-11-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Restricted Stock Units |
M - Exercise | −2 394 | 31 124 | −7,14 | ||||
| 2021-11-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Restricted Stock Units |
M - Exercise | −5 129 | 51 294 | −9,09 | ||||
| 2021-11-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
F - Taxes | −3 730 | 4 722 804 | −0,08 | 47,25 | −176 242 | 223 152 489 | |
| 2021-11-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 7 523 | 4 726 534 | 0,16 | ||||
| 2021-11-09 | 3/A | LIAN |
LianBio
Ordinary Shares |
5 002 792 | ||||||||
| 2021-08-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Restricted Stock Units |
M - Exercise | −2 394 | 33 518 | −6,67 | ||||
| 2021-08-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Restricted Stock Units |
M - Exercise | −5 129 | 56 423 | −8,33 | ||||
| 2021-08-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
F - Taxes | −3 730 | 4 719 011 | −0,08 | 49,48 | −184 560 | 233 496 664 | |
| 2021-08-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 7 523 | 4 722 741 | 0,16 | ||||
| 2021-05-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Restricted Stock Units |
M - Exercise | −2 394 | 35 912 | −6,25 | ||||
| 2021-05-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Restricted Stock Units |
M - Exercise | −5 130 | 61 552 | −7,69 | ||||
| 2021-05-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
F - Taxes | −3 731 | 4 715 218 | −0,08 | 53,66 | −200 205 | 253 018 598 | |
| 2021-05-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 7 524 | 4 718 949 | 0,16 | ||||
| 2021-02-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
F - Taxes | 16 000 | 4 711 425 | 0,34 | 62,50 | 1 000 000 | 294 464 062 | |
| 2021-02-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Restricted Stock Units |
M - Exercise | −5 129 | 66 682 | −7,14 | ||||
| 2021-02-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
F - Taxes | −2 139 | 4 695 425 | −0,05 | 64,98 | −138 992 | 305 108 716 | |
| 2021-02-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 5 129 | 4 697 564 | 0,11 | ||||
| 2021-02-12 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Restricted Stock Units |
A - Award | 38 306 | 38 306 | |||||
| 2021-02-12 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Stock Option (Right to Buy) |
A - Award | 225 971 | 225 971 | |||||
| 2021-02-12 |
|
5 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
G - Gift | 268 000 | 1 195 686 | 28,89 | ||||
| 2021-02-12 |
|
5 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
G - Gift | −472 650 | 1 612 722 | −22,67 | ||||
| 2020-11-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Restricted Stock Units |
M - Exercise | −5 129 | 71 811 | −6,67 | ||||
| 2020-11-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
F - Taxes | −1 774 | 4 692 435 | −0,04 | 44,33 | −78 641 | 208 015 644 | |
| 2020-11-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 5 129 | 4 694 209 | 0,11 | ||||
| 2020-08-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Restricted Stock Units |
M - Exercise | −5 129 | 76 940 | −6,25 | ||||
| 2020-08-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
F - Taxes | −1 774 | 4 689 080 | −0,04 | 28,53 | −50 612 | 133 779 452 | |
| 2020-08-18 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 5 129 | 4 690 854 | 0,11 | ||||
| 2020-08-05 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −6 759 | 2 085 372 | −0,32 | 27,36 | −184 914 | 57 052 024 |
| 2020-08-05 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −7 184 | 2 092 131 | −0,34 | 26,70 | −191 846 | 55 869 522 |
| 2020-08-05 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −3 040 | 2 099 315 | −0,14 | 28,12 | −85 498 | 59 041 975 |
| 2020-08-05 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −63 017 | 2 102 355 | −2,91 | 27,23 | −1 715 808 | 57 242 291 |
| 2020-07-06 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −56 445 | 2 165 372 | −2,54 | 30,22 | −1 706 022 | 65 447 286 |
| 2020-07-06 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −2 700 | 2 221 817 | −0,12 | 32,42 | −87 520 | 72 020 198 |
| 2020-07-06 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −33 700 | 2 224 517 | −1,49 | 31,67 | −1 067 343 | 70 454 680 |
| 2020-07-06 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −50 625 | 2 258 217 | −2,19 | 30,63 | −1 550 472 | 69 161 509 |
| 2020-06-10 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −10 600 | 2 308 842 | −0,46 | 30,01 | −318 125 | 69 292 504 |
| 2020-06-05 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Restricted Stock Units |
A - Award | 82 069 | 82 069 | |||||
| 2020-06-05 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Stock Option (Right to Buy) |
A - Award | 590 551 | 590 551 | |||||
| 2020-06-05 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −5 930 | 2 319 442 | −0,26 | 30,05 | −178 173 | 69 690 186 |
| 2020-06-03 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −8 709 | 2 325 372 | −0,37 | 29,71 | −258 711 | 69 077 966 |
| 2020-06-03 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −71 291 | 2 334 081 | −2,96 | 29,13 | −2 076 678 | 67 990 846 |
| 2020-05-06 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −34 834 | 2 405 372 | −1,43 | 31,23 | −1 088 012 | 75 129 870 |
| 2020-05-06 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −44 766 | 2 440 206 | −1,80 | 30,86 | −1 381 470 | 75 304 269 |
| 2020-05-05 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −33 974 | 2 484 972 | −1,35 | 29,77 | −1 011 494 | 73 984 077 |
| 2020-05-05 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −5 706 | 2 518 946 | −0,23 | 29,13 | −166 191 | 73 365 814 |
| 2020-05-05 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −4 098 | 2 524 652 | −0,16 | 29,78 | −122 055 | 75 194 235 |
| 2020-05-05 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −36 622 | 2 528 750 | −1,43 | 29,06 | −1 064 345 | 73 493 061 |
| 2020-04-09 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −1 805 | 2 565 372 | −0,07 | 25,48 | −45 983 | 65 353 878 |
| 2020-04-06 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −100 | 2 567 177 | 0,00 | 25,10 | −2 510 | 64 436 143 |
| 2020-04-06 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −200 | 2 567 277 | −0,01 | 25,09 | −5 018 | 64 412 980 |
| 2020-04-03 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −15 778 | 2 567 477 | −0,61 | 25,04 | −395 103 | 64 293 219 |
| 2020-04-03 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −1 382 | 2 583 255 | −0,05 | 28,20 | −38 979 | 72 860 191 |
| 2020-04-03 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −12 976 | 2 584 637 | −0,50 | 27,45 | −356 252 | 70 960 433 |
| 2020-04-03 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −20 040 | 2 597 613 | −0,77 | 26,38 | −528 623 | 68 520 875 |
| 2020-04-03 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −27 719 | 2 617 653 | −1,05 | 25,52 | −707 508 | 66 813 760 |
| 2020-03-04 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −201 | 2 645 372 | −0,01 | 33,22 | −6 677 | 87 880 581 |
| 2020-03-04 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −12 090 | 2 645 573 | −0,45 | 32,60 | −394 105 | 86 239 330 |
| 2020-03-04 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −7 756 | 2 657 663 | −0,29 | 31,76 | −246 365 | 84 419 336 |
| 2020-03-04 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −995 | 2 665 419 | −0,04 | 33,33 | −33 159 | 88 828 020 |
| 2020-03-04 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −59 305 | 2 666 414 | −2,18 | 32,53 | −1 929 411 | 86 748 313 |
| 2020-03-04 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −39 653 | 2 725 719 | −1,43 | 31,88 | −1 264 312 | 86 907 915 |
| 2020-02-14 |
|
5/A | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
G - Gift | 66 730 | 4 685 725 | 1,44 | ||||
| 2020-02-14 |
|
5/A | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
G - Gift | −400 375 | 0 | −100,00 | ||||
| 2020-02-13 |
|
5 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
G - Gift | 66 730 | 4 685 365 | 1,44 | ||||
| 2020-02-13 |
|
5 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
G - Gift | −400 375 | 0 | −100,00 | ||||
| 2020-02-07 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −30 893 | 2 765 372 | −1,10 | 34,87 | −1 077 390 | 96 442 072 |
| 2020-02-05 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −54 951 | 2 796 265 | −1,93 | 34,55 | −1 898 387 | 96 602 287 |
| 2020-02-05 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −2 100 | 2 851 216 | −0,07 | 35,20 | −73 914 | 100 354 820 |
| 2020-02-05 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −32 056 | 2 853 316 | −1,11 | 34,92 | −1 119 309 | 99 630 091 |
| 2020-01-06 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −6 668 | 2 885 372 | −0,23 | 32,88 | −219 250 | 94 873 628 |
| 2020-01-06 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −77 271 | 2 892 040 | −2,60 | 32,14 | −2 483 706 | 92 958 263 |
| 2020-01-06 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −100 | 2 969 311 | 0,00 | 35,17 | −3 517 | 104 430 668 |
| 2020-01-06 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −5 077 | 2 969 411 | −0,17 | 34,19 | −173 560 | 101 511 097 |
| 2020-01-06 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −19 793 | 2 974 488 | −0,66 | 33,41 | −661 342 | 99 386 270 |
| 2020-01-06 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
S - Sale | X | −11 091 | 2 994 281 | −0,37 | 32,55 | −361 042 | 97 471 931 |
| 2019-07-08 |
|
4 | EIDX |
Eidos Therapeutics, Inc.
Common Stock |
P - Purchase | 882 353 | 24 575 501 | 3,72 | 29,90 | 26 382 796 | 734 819 768 | |
| 2019-07-03 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Management Incentive Units |
M - Exercise | −1 907 102 | 0 | −100,00 | ||||
| 2019-07-03 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Management Incentive Units |
M - Exercise | −2 744 459 | 0 | −100,00 | ||||
| 2019-07-03 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Management Incentive Units |
M - Exercise | −927 686 | 0 | −100,00 | ||||
| 2019-07-03 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Management Incentive Units |
M - Exercise | −1 742 631 | 0 | −100,00 | ||||
| 2019-07-03 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Series B Units |
M - Exercise | −400 375 | 0 | −100,00 | ||||
| 2019-07-03 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Units |
M - Exercise | −906 905 | 0 | −100,00 | ||||
| 2019-07-03 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Units |
M - Exercise | −323 270 | 0 | −100,00 | ||||
| 2019-07-03 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 927 686 | 927 686 | |||||
| 2019-07-03 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 400 375 | 400 375 | |||||
| 2019-07-03 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 1 907 102 | 7 624 367 | 33,36 | ||||
| 2019-07-03 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 2 744 459 | 5 717 265 | 92,32 | ||||
| 2019-07-03 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 1 742 631 | 2 972 806 | 141,66 | ||||
| 2019-07-03 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 906 905 | 1 230 175 | 280,54 | ||||
| 2019-07-03 |
|
4 | BBIO |
BridgeBio Pharma, Inc.
Common Stock |
M - Exercise | 323 270 | 323 270 | |||||
| 2019-06-27 | 3 | BBIO |
BridgeBio Pharma, Inc.
No securities beneficially owned. |
0 | ||||||||
| 2019-05-29 |
|
4 | EIDX |
Eidos Therapeutics, Inc.
Common Stock |
P - Purchase | 1 103 848 | 23 693 148 | 4,89 | 25,93 | 28 622 779 | 614 363 328 | |
| 2018-06-22 |
|
4 | EIDX |
Eidos Therapeutics, Inc.
Series Seed Preferred Stock |
C - Conversion | −12 832 123 | 0 | −100,00 | ||||
| 2018-06-22 |
|
4 | EIDX |
Eidos Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | −2 909 029 | 0 | −100,00 | ||||
| 2018-06-22 |
|
4 | EIDX |
Eidos Therapeutics, Inc.
Series B Convertible Preferred Stock |
X - Other | 332 262 | 2 909 029 | 12,89 | ||||
| 2018-06-22 |
|
4 | EIDX |
Eidos Therapeutics, Inc.
Warrants |
X - Other | −332 262 | 0 | −100,00 | ||||
| 2018-06-22 |
|
4 | EIDX |
Eidos Therapeutics, Inc.
Common Stock |
P - Purchase | 1 000 000 | 19 614 655 | 5,37 | 17,00 | 17 000 000 | 333 449 135 | |
| 2018-06-22 |
|
4 | EIDX |
Eidos Therapeutics, Inc.
Common Stock |
F - Taxes | −211 762 | 18 614 655 | −1,12 | 17,00 | −3 599 954 | 316 449 135 | |
| 2018-06-22 |
|
4 | EIDX |
Eidos Therapeutics, Inc.
Common Stock |
C - Conversion | 18 826 417 | 18 826 417 |
